RGRNA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Cosmos Global Digital Miners Access ETF
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cosmos Global Digital Miners Access ETF - ORDINARY FULLY PAID DEFERRED
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RGRNA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RGRNA
N/A
RGRNA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in RGRNA also invest in...
Want more shares? Try these...
RGS
Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.
🙌 Performance (5Yr p.a)
-17.54%
📊 Share price
$0.01 AUD
🧬 BIOTECHNOLOGY
